The Longevity Podcast: Alzheimer's and Brain Health Research

Send us Fan Mail

How often does dementia show up in older adults who live at home but need advanced care such as tube feeding, breathing support, catheters, stoma or enema care, wound or pain care, or dialysis? A nationwide survey in Taiwan visited 11,297 community-dwelling older adults between 2020 and 2022. About 6.5% received at least one kind of advanced care, and in that group dementia was more than twice as common (18.0% vs 8.0%). The highest odds were seen with stoma or enema care, tube feeding, dialysis, urinary catheters, and respiratory care. Among people with dementia, day-night confusion and resistance to...

Send us Fan Mail

New anti-amyloid antibody treatments for early Alzheimer's are now authorized in Europe, but how many patients in a real memory clinic actually qualify? A team in Modena, Italy, applied the Italian appropriate use recommendations step by step to all 1,080 patients seen at their cognitive neurology clinic in 2024 and 2025. Of those, 596 had mild cognitive impairment or mild Alzheimer's dementia, 230 had biomarker-confirmed Alzheimer's, and 50 ended up treatment-ready. That is 4.6% of the clinic, 8.4% of people with a mild clinical diagnosis, and 21.7% of those with confirmed biomarkers. The biggest hurdles were having moved past the mild stage...

Send us Fan Mail

Can the conditions of everyday life, like money, stress, schooling, neighborhood, and access to care, leave a mark on the brain by age 40? Using the CARDIA study, researchers built a 12-item social determinants of health index across five domains and followed 3,488 adults from early midlife, 645 of them with repeated brain MRI. People in the most disadvantaged group already scored lower on thinking tests at the start. Over each five-year stretch they also showed faster decline in processing speed, faster build-up of white matter hyperintensities (small signs of blood-vessel damage), and faster loss of...

Send us Fan Mail

Can loneliness, depression, and stress make your body age faster on the inside? Researchers pooled 22 studies of adults from midlife onward that measured "epigenetic age," a biological age estimated from DNA methylation patterns in blood. Greater loneliness, depression, and psychosocial stress were each linked to faster epigenetic aging, most consistently on newer clocks such as PhenoAge and GrimAge that track health and lifespan. The links were modest, and they show association rather than cause. The authors point out that no eligible studies looked at anxiety, that all included studies came from Western countries...

Send us Fan Mail

At what age does measurable thinking decline actually begin? Researchers pooled long-term data on 14,389 adults aged 22 to 94 from three population studies in China, the United States, and the Czech Republic, putting different cognitive tests on a common 0 to 100 scale and following people for an average of seven to nine years. A small but detectable drop in overall cognition first showed up in the 31 to 40 age group and grew steadily larger with age. Non-memory skills such as attention and executive function showed change from about age 31, while significant memory decline appeared only after 50. Individual...

Send us Fan Mail

The choroid plexus is the tissue inside the brain's ventricles that makes cerebrospinal fluid and helps clear waste. Earlier imaging studies found it grows larger across the Alzheimer's continuum, but few had checked that against autopsy, the gold standard for diagnosis. Toronto researchers used National Alzheimer's Coordinating Center data on 111 people who had a brain MRI within five years of death and a post-mortem exam. A larger choroid plexus, adjusted for head size, went along with intermediate and high levels of Alzheimer's pathology and with cognitive impairment, while women had smaller volumes than...

Send us Fan Mail

Special care units for people with dementia who have agitation and other behavioral symptoms offer a home-like setting with specialized staff. But are they worth the money? The European RECage study followed 508 people for three years across Italy, Switzerland, Germany, Norway, France, and Greece, comparing those cared for in these units with those who were not. Over three years, the special care unit group had slightly fewer quality-adjusted life years (about 0.13 fewer) and roughly €25,000 higher total costs, so the units were likely not cost-effective in this analysis. Because the study was observational and th...

Send us Fan Mail

Machine learning can forecast how fast thinking skills will slip — but how well do those models work on a new group of patients? Researchers in Zurich trained models on ADNI (1,237 people) and OASIS-3 (662 people) to predict yearly change in CDR-SOB and MMSE scores. Adding structural MRI to clinical and demographic data improved predictions inside each dataset (R² up to about 0.41–0.42 for CDR-SOB). When the same models were tested on the other cohort, performance dropped (R² roughly 0.18–0.35). Slimming the models to only the top predictors did about as well externally, which points to redundant features...

Send us Fan Mail

Can the shape of your brain's memory center reveal risk that amyloid tests miss? Researchers at UC Irvine studied MRI scans and up to 10 years of follow-up in 1,142 dementia-free older adults from the Alzheimer's Disease Neuroimaging Initiative. Smaller overall hippocampal volume tracked with worse thinking and faster decline in every area tested. But a bigger size difference between the left and right hippocampus was tied specifically to memory decline, and it predicted progression to dementia only in people without detectable amyloid. The authors suggest hippocampal asymmetry may flag brain changes that go beyond...

Send us Fan Mail

Could a routine eye exam one day flag Alzheimer's disease? Because the retina is an extension of the brain, this study used a genetic method called Mendelian randomization, drawing on large genetic datasets and more than 52,000 UK Biobank participants, to sort out which eye changes Alzheimer's actually causes. Genetic risk for Alzheimer's was linked to more twisted small arteries in the retina, with weaker hints of thinning in the inner retinal layers. An apparent link between optic disc size and Alzheimer's was probably explained by refractive error. The authors say more work is...

Send us Fan Mail

Enlarged perivascular spaces, the fluid-filled channels around small blood vessels in the brain, show up on routine MRI. This study of 307 people with cognitive impairment from a Seoul dementia cohort asked whether amyloid and blood vessel disease leave different patterns of these spaces.

Vascular burden was linked to more enlarged spaces deep in the basal ganglia, regardless of amyloid. Amyloid and vascular disease were each linked to more spaces in the parietal, temporal, and occipital white matter, with no extra increase when both were present. The spatial pattern may help hint...

Send us Fan Mail

How do clinicians tell mild dementia from moderate dementia? This study tested the Functional Activities Questionnaire, an informant-based checklist of everyday tasks, in more than 34,000 people from the US NACC database and confirmed the results in the ADNI and FTLDNI cohorts. A score of 18 or higher caught 96% of moderate dementia cases, while a cut-off of 23 traded a little sensitivity for higher specificity. Older age and lower cognitive scores made misclassification more likely.

Source: Ersözlü E, et al., Drawing a line: Differentiating mild from moderate dementia using the functional activities questionnaire, J...

Send us Fan Mail

Using amyloid and tau PET scans from two US cohorts, ADNI and the Harvard Aging Brain Study, researchers estimated how long it takes to go from amyloid positivity to tau positivity. That interval varied widely and was shorter in APOE4 carriers, women, and people who became amyloid positive at older ages. A shorter amyloid-to-tau interval predicted earlier symptom onset, pointing to a narrower window for early detection in these groups.

Source: Milà-Alomà M, et al., The time interval from amyloid to tau PET positivity varies by age, sex and APOE-ε4 sta...

Send us Fan Mail

A gut bacterial compound called imidazole propionate (ImP) is linked to Alzheimer's-related brain changes and faster cognitive decline in a large Wisconsin cohort, with mouse and cell studies pointing to barrier and tau pathways.

Researchers measured blood ImP in nearly 1,200 mostly cognitively unimpaired adults, connected ImP-producing gut bacteria to disease markers, and found a genetic signal tied to both ImP levels and Alzheimer's risk. In mice, chronic ImP worsened Alzheimer-like pathology.

This episode is an AI deep-dive overview of the open-access Nature Communications paper. It sticks to what the...

Send us Fan Mail

A Mendelian randomization study of plasma proteins, structural MRI measures, and Alzheimer's disease risk found 12 neuroimaging metrics and 1,633 proteins with causal ties to AD. Brain imaging also mediated about 67% of the link between the immune-related protein PTPRC and Alzheimer's risk across the disease course.

Source: Xu X, et al., Bidirectional causal relationships between plasma proteins, neuroimaging metrics and risk of Alzheimer's disease, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100619 (CC BY 4.0)

This podcast is created by Ai for educational and entertainment purposes only and...

Send us Fan Mail

A China-wide survey of 1,057 older adults with Alzheimer's or related cognitive impairment found 73.5% had at least one safety incident in the past year, and over a third reported three or more. Medication errors and verbal aggression were the most common, followed by falls and physical aggression. Medication errors and getting lost also sat at the center of how different incidents linked together across care settings and regions.

Source: Zhou Y, et al., Mapping the nature, type, and association network of safety incidents among individuals with cognitive impairment in China: a large-scale...

Send us Fan Mail

A letter in JPAD argues that a reported safety advantage for an anti-amyloid antibody drug, in a European-label subgroup of its phase 3 trial, may largely reflect excluding patients on blood thinners. About one in four people with Alzheimer's take those medicines in real-world data, so the subgroup findings may not apply in everyday practice.

Source: Ijaz A, Mohyudin G, The generalizability gap: anticoagulant exclusions and the "Enhanced Safety" of donanemab in the EU-eligible population, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100628 (CC BY-NC-ND 4.0)

This podcast is created...

Send us Fan Mail

A letter responds to a large review of public dementia risk awareness, arguing that recognizing a risk factor is not the same as knowing what to do about it. The authors urge surveys to measure actionable knowledge, whether risks are personal habits or policy problems, and to separate fear and stigma from true risk perception.

Source: Xie Z, Su J, Liao T, Beyond recognition: Refining the assessment of public knowledge and risk perception in dementia prevention, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100602 (CC BY 4.0)

Send us Fan Mail

When Europe approved donanemab and lecanemab, the label was narrower than the trials: early Alzheimer's, APOE ε4 non-carriers or heterozygotes, plus extra exclusions. This editorial walks through why EU-eligible subgroup analyses matter—and how Jessen's TRAILBLAZER-ALZ 2 re-analysis shows benefit and safety still hold (even improve a bit) in the patients clinicians actually treat.

Source: Grimmer T, From trial population to treated population: why EU-eligible subgroup analyses matter for anti-amyloid immunotherapy, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100665 (CC BY-NC-ND 4.0)

This podcast is created by Ai for educational and ent...

Send us Fan Mail

How does toxic Tau leave the brain? In this editorial, Vincent Prévot and colleagues spotlight tanycytes—specialized cells lining the third ventricle that shuttle Tau from cerebrospinal fluid into the blood. In Alzheimer's disease these cells are fragmented and their transport genes look dysregulated, which may worsen Tau buildup and open a new therapeutic angle.

Source: Prévot V, Schwaninger M, Nogueiras R, Rasika S, Tau-ing and fro-ing: the tanycytic shuttle in neurodegeneration, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100643 (CC BY-NC-ND 4.0)

This podcast is created by A...

Send us Fan Mail

Should doctors check brain health the way they check blood pressure? In this editorial, neurologist Gregory Cooper looks at the Brain Health Vital Signs project, which scores patients on 15 lifestyle risk factors for dementia. He explains how the FINGER, US POINTER, and LatAm-FINGERS trials showed that exercise, diet, mental challenge, social connection, and heart health can protect thinking skills, and why clinics now need practical ways to help patients with memory problems follow that advice.

Source: Cooper G, Is it time to make brain health a vital sign...

Send us Fan Mail

Even patients chasing new Alzheimer's antibody drugs often skip the lifestyle basics that protect the brain. A Brain Health Vital Signs study of 150 people with early Alzheimer's found fewer than 3% met all 15 consensus recommendations, with the biggest gaps in exercise, mood and stress, blood sugar, blood pressure, and weight. Those pursuing anti-amyloid therapy looked no better than those who were not.

Source: Daffner KR, Riera K, Ghorayeb GR, McFeeley BM, Weizenbaum E, Willment K, Gale SA, Suboptimal adherence to brain health recommendations in patients pursuing anti-amyloid antibody therapy for Alzheimer's disease...

Send us Fan Mail

Most brain-healthy diet advice, like the Mediterranean and MIND diets, comes from studies of Western populations. In this editorial, Lei Feng of the National University of Singapore responds to a new review of diet and Alzheimer's risk across East and West. He highlights the Shanghai Cognitive Diet Pattern, which is built around what Chinese adults actually eat, and explains why whole dietary patterns tell us more than single nutrients. He also points to mixed trial results, including the MIND Diet Trial, which didn't beat its control diet, and argues for culturally adapted, personalized...

Send us Fan Mail

Does what you eat shape your risk of Alzheimer's disease, and does the answer change between Eastern and Western diets? This episode digs into a 2026 review in the Journal of Prevention of Alzheimer's Disease that compares dietary patterns across East and West, including the Mediterranean and MIND diets and traditional Asian eating patterns, and what the evidence says about future diet-based prevention strategies for dementia and brain health.

Source: Jiang et al., "Dietary patterns and Alzheimer's disease: East-west perspectives and future intervention strategies," J Prev Alzheimers Dis. 2026. https://doi.org/10.1016/j...

Send us Fan Mail

People with atrial fibrillation (AFib), a common irregular heart rhythm, face a higher risk of developing dementia. This study followed 91,795 UK Biobank participants who wore activity trackers. It found that people with AFib who got at least 150 minutes a week of moderate-to-vigorous activity had a lower AFib-related dementia risk. Interestingly, the activity people reported themselves only loosely matched what the trackers measured, and self-reported activity wasn't linked to lower dementia risk. The findings suggest that staying active may help protect brain health in people with AFib, though longer studies are needed to confirm...

Send us Fan Mail

Your brain’s future might be readable from your cardiovascular risk score right now. We walk through a dense but deeply practical research paper from the Journal of Prevention of Alzheimer’s Disease that links 10-year ASCVD risk to the pace of cognitive decline, without needing a brain scan to spot the warning signs. The big idea is simple: cognitive preservation is not just a neuroscience problem. It is a vascular health problem, and the “plumbing” shows up in numbers you can measure today.

We trace the study’s real-world setting in Project...

Send us Fan Mail

You know that moment when you open the refrigerator and forget what you came for, or you recognize an actor’s face but their name is gone? Most of us laugh it off, but the fear behind it is real: what if it’s not stress or sleep, but the earliest sign of Alzheimer’s disease?

We break down a landmark 2026 study that asks a surprisingly uncomfortable question: who is the more reliable narrator of your cognitive health, you or the person closest to you? Using the Everyday Cognition (ECog) questionnaire across...

Send us Fan Mail

Imagine learning that your brain is on a specific trajectory toward memory loss and you find out from a routine blood draw, not a spinal tap, not a hard-to-access PET scan. That future is arriving fast, and it’s creating a new challenge: we don’t have one “Alzheimer’s blood test” anymore. We have a growing menu of brain biomarkers, each reporting on a different kind of cellular crisis, and the only way to use them well is to match the marker to the underlying biology.

We walk through four of the big...

Send us Fan Mail

You can “pass” a memory test and still reveal something chilling: your brain can confidently invent a word that was never said. We start there because that tiny intrusion error, caught by the right kind of neuropsychological scoring, may be one of the earliest objective signals of Alzheimer’s disease long before you lose your keys or miss an appointment.

We unpack a 2026 narrative review that argues Alzheimer’s isn’t a sudden drop from healthy to sick, but a decades-long biological process. The centerpiece is Objectively Defined Subtle Cognitive Decline (ObjSCD), a...

Send us Fan Mail

In the European Union, the Alzheimer's drug donanemab is approved for a narrower group of people with early symptomatic Alzheimer's disease. They must carry no copies or one copy of the APOE ε4 gene variant, and they can't have certain signs of brain bleeding, uncontrolled high blood pressure, or be taking blood thinners. This analysis of the TRAILBLAZER-ALZ 2 trial looked only at participants who would meet those EU criteria. In that group, donanemab slowed disease progression compared with placebo, and the benefit grew over 154 weeks of follow-up. The safety profile was described as manageable, t...

Send us Fan Mail

Alzheimer’s has been treated like a neuron problem for decades, but what if the real lever sits in the brain’s support system, quietly failing long before symptoms show up? We dig into a 2026 Journal of Prevention of Alzheimer’s Disease paper that uses a massive transcriptomic dragnet across multiple human datasets to spotlight one surprising hub: CD44, a receptor best known outside the brain, now showing up as a major signal across vulnerable Alzheimer’s regions.

We walk through why amyloid plaque clearing therapies can slow decline yet still come wit...

Send us Fan Mail

Your shoulders creep toward your ears during a brutal month. Your chest tightens during panic. Your body feels heavy during depression. We usually call those downstream symptoms, but the research we’re unpacking argues for something far more disruptive: fascia may help generate the very emotional states we blame on the brain alone.

We walk through a major 2026 review that reframes fascia as a continuous, body-wide sensory network rather than inert “wrapping paper.” From superficial fascia under the skin to deep fascia that transmits force, visceral fascia that lets organs glide, and pa...

Send us Fan Mail

What if the clearest signal about your brain’s future isn’t hidden inside an MRI, but floating in your blood right now? We dig into Neurofilament Light Chain (NFL), a nervous system biomarker that behaves like a smoke alarm for ongoing nerve damage and could help shift brain health from reactive to proactive.

We anchor the story in a remarkable study of 495 Japanese centenarians followed for up to 17 years. Researchers measured amyloid beta, phosphorylated tau, and NFL, and NFL came out on top for predicting cognitive function and mortality risk. That...

Send us Fan Mail

You’ve heard the standard dementia prevention script: eat well, sleep more, do the puzzles, and hope for good genes. Then a result lands that doesn’t fit the script at all, a routine shingles vaccine associated with a 33% lower risk of dementia in a real-world study of 1.5 million Medicare patients. We dig into what that finding does and does not mean, why it’s so hard to dismiss, and how it compares to the modest wins medicine has chased for decades with expensive Alzheimer’s drugs. 

From there, we follow the scien...

Send us Fan Mail

Alzheimer’s has been sold to all of us as a neuron story: plaques, tangles, and brain cells fading away. But the data we walk through here points to a more unsettling possibility that the real tipping point is structural. When the brain’s blood vessels fail, memory can fall apart even faster, and what looks like “classic Alzheimer’s dementia” may actually be a vascular collapse hiding in plain sight.

We unpack a large autopsy analysis from the NACC database and use it to zoom in on cerebral amyloid angiopathy (CAA), wher...

Send us Fan Mail

A medical breakthrough can still fail at the pharmacy counter. We finally have amyloid-targeting drugs for early-stage Alzheimer’s disease, and they are already on the market, but several major health systems have looked at the same evidence and refused to pay. That contradiction is the mystery we unpack, using the explosive Glasgow IPCAD meeting as our guide to what’s really blocking access.

We dig into the three barriers driving negative reimbursement decisions: headline drug prices, serious safety risks that require ongoing MRI monitoring, and the hardest problem of all, long...

Send us Fan Mail

A camera watches you walk across a room and can estimate your biological age. That sounds like science fiction until you see the data and the logic behind it. We break down a 2026 multidimensional modeling study that replaces the idea of “age as a number” with age as measurable wear and tear across your body and brain, using tools that are surprisingly practical: a marker-free 3D gait camera, a VR eye-tracking test, a soft fNIRS cap for brain connectivity, and a simple blood draw.

We start with gait analysis and the over...

Send us Fan Mail

Depression and dementia get talked about like two separate problems, until you ask the uncomfortable question: which one comes first? We dig into a huge 22-year longitudinal study (over 13,000 Americans in the Health and Retirement Study) to figure out whether depressive symptoms are a modifiable dementia risk factor or an early clinical warning sign of Alzheimer’s disease and related neurodegenerative pathology.

The timeline turns out to be the tell. When depressive symptoms show up in late midlife (ages 50 to 59), dementia risk jumps dramatically, and the relationship holds even after researchers ex...

Send us Fan Mail

Think your daily health choices only matter for your heart and waistline? The research we’re unpacking challenges that assumption and makes a sharper, more urgent claim: the same habits may interact with silent Alzheimer’s pathology in your brain years before any symptom shows up. We walk through a major analysis combining the A4 and LEARN cohorts (1,707 cognitively unimpaired adults ages 65 to 85) and explain how PET scans split people into amyloid beta positive and amyloid beta negative groups, then track cognitive change for nearly five years.

The headline result is as u...

Send us Fan Mail

Fish oil has a near-halo status in nutrition culture: a simple, golden capsule that promises better memory, sharper thinking, and protection from cognitive decline. But a landmark longitudinal analysis using ADNI data and published in the Journal of Prevention of Alzheimer’s Disease forces a rethink, suggesting omega-3 supplement use in older adults may be linked to accelerated decline on major cognitive and functional scales. That tension between “common wisdom” and long-term human data is where we start, and we don’t let easy explanations off the hook. 

We walk through how the r...